Local Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: Clinical, Histological and Ultrastructural Patterns

REFERENCES

• Brosman SA. Experience with bacillus Calmette Guerin in patients with superficial bladder carcinoma. J Urol 1982; 128: 27–30.
   PubMed Web of Science ®Google Scholar
• Catalona WJ. Risks and benefits of repeated courses of intravesical BCG therapy for superficial bladder cancer. J Urol 1987; 137: 220–224.
   PubMed Web of Science ®Google Scholar
• Coe JE, Feldman JD. Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology 1966; 10: 127–130.
   PubMed Web of Science ®Google Scholar
• De Kernion JB, Huang MY, Lindner A, Smith RB, Kaufman JJ. Management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin. J Urol 1982; 133: 598–601.
   Google Scholar
• Garnick MB, Richie JP. Intravesical adriamycin for multiple recurrent superficial bladder cancer. Evaluation at 6 years of follow-up. (Abstract No. 299.) Am Urol Assoc. J Urol 1987; 137: 178A.
   Web of Science ®Google Scholar
• Hardeman SW, Paerry A, Soloway MS. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder. J Urol 1988; 140: 289–292.
   PubMed Web of Science ®Google Scholar
• Herr HW, Pinsky CM, Melamed MR, Whitmore WF. Long term effect of intravesical BCG on flat carcinoma in situ (CIS) of the bladder. (Abstract No. 144.) Am Urol Assoc. J Urol 1984; 131: 139A.
   PubMedGoogle Scholar
• Herr HV, Pinsky CM, Whitemore WF, Sogani PG, Oettgen HF, Melamed MR. Experience with intravesical BCG therapy of superficial bladder tumors. Urology 1985; 25: 119–123.
   PubMed Web of Science ®Google Scholar
• Hillyard RW, Ladaga L, Schellhammer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical BCG. J Urol 1988; 139: 290–293.
   PubMed Web of Science ®Google Scholar
• Jakse G, Hostadter F, Marberger H. Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol 1981; 125: 185–188.
   PubMed Web of Science ®Google Scholar
• Jones HC, Swinney J. Thiotepa in the treatment of tumors of the bladder. Lancet 1961; 2: 615–619.
   PubMed Web of Science ®Google Scholar
• Khanna OP, Son DL, Mazer H, Read J, Nugent D, Cottone R, Heeg M, Rezvan M, Viek N, Uhlman R, Friedmann M. Superficial bladder cancer treated with intravesical BCG or adriamicin: follow-up report. Urology 1988; 31: 287–292.
   PubMed Web of Science ®Google Scholar
• Kurth KH, Debruyne FJM, Senge T, Carpentier PJ, Risdl H, Sylvester R, De Pauw M. Adjuvant chemotherapy of superficial transitional cell carcinoma: an EORTC randomized trial comparing doxorubicin hydrochioride, ethoglucid acid and TUR alone. Prog Clin Biol Res 1985; 162A: 135–138.
   Google Scholar
• Lamm DL, Sarosdy M, Gran DA, Buchanan J, Hunt Y, De Haven J, Morgantown WV. Randomized prospective comparison of intravesical mice BCG immunotherapy with and without percutaneous administration. (Abstract No. 55.) Am Urol Assoc. J Urol 1988; 139: 300A.
   Google Scholar
• Lamm DL, Stogdill VD, Stogdill BJ, Cristen RG. Complications of BCG immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135: 272–274.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Thor DE, Winter WD, Stogdill VD, Radwin HM. BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer 1981; 48: 82–86.
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180–183.
   PubMed Web of Science ®Google Scholar
• Morales A. Long term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol 1984; 132: 457–459.
   PubMed Web of Science ®Google Scholar
• Niijima T, Koiso K, Adaza H. Randomized clinical trial for chemoprophylaxis of recurrence in superficial bladder cancer. In: Spitzy, KH Karrer, eds. Proceedings of the 13th international Congress of Chemotherapy, Vienna, 1983: 246–248.
   Google Scholar
• Pinsky CM, Camacho FJ, Kerr D, Braun DW, Whitmore WF, Oettgen HF. Treatment of superficial bladder cancer with intravesical BCG. In: Immunotherapy of human cancer. Terry WD, Rosenberg SA, eds. New York: Elsevier North Holland, 1982: Sect. VII: 309–313.
   Google Scholar
• Rawls WH, Lamm VD, Eyolfson MF. Septic complications in the use of BCG for non invasive transitional cell carcinoma. (Abstract No. 552.) Am Urol Assoc. J Urol 1988; 139: 300 A.
   Google Scholar
• Reynolds RH, Stogdill VD, Lamm DL. Disease progression in BCG-treated patients with transitional cell carcinoma of the bladder. (Abstract No. 392.) Am Urol Assoc. J Urol 1985; 133: 211 A.
   Google Scholar
• Schellhammer PF, Ladaga LE, Fillion MB. BCG for superficial transitional cell carcinoma of the bladder. J Urol 1986; 135: 261–264.
   PubMed Web of Science ®Google Scholar
• Schulman CC, Robinson M, Denis E, Smith P, Viggiano G, De Pauw M, Dacesio O, Sylvester R. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, VM-26 and TUR alone. Eur Urol 1982; 8: 207–212.
   PubMed Web of Science ®Google Scholar
• Steg A, Lelev C, Debré B. Boccon-Gibod L. Systemic BCG infection in patients treated by intravesical BCG therapy for bladder cancer. (Abstract No. 551.) Am Urol Assoc. J Urol 1988; 139: 300A.
   Google Scholar
• Zincke H, Benson RC, Fleming TR, Myres RP, Barrett DM. Tumor recurrence after intravesical instillation of thiotepa and mitomycin C at time of transurethral resection of the bladder cancer (Ta-Tcis) and postoperatively. (Abstract No. 139.) Am Urol Assoc. J Urol 1984; 131: 138A.
   Google Scholar